Mealey's (March 26, 2021, 12:45 PM EDT) -- SAN DIEGO — Sixteen days after a California federal judge granted summary judgment in the incretin mimetic multidistrict litigation on the basis of preemption, experts and causation, four diabetes drug manufacturers on March 24 filed motions for a total of $686,002 in attorney fees and costs to be assessed against the plaintiffs....